[go: up one dir, main page]

PE20001641A1 - Ligandos de receptores de melanocortina - Google Patents

Ligandos de receptores de melanocortina

Info

Publication number
PE20001641A1
PE20001641A1 PE2000000267A PE0002672000A PE20001641A1 PE 20001641 A1 PE20001641 A1 PE 20001641A1 PE 2000000267 A PE2000000267 A PE 2000000267A PE 0002672000 A PE0002672000 A PE 0002672000A PE 20001641 A1 PE20001641 A1 PE 20001641A1
Authority
PE
Peru
Prior art keywords
alkyl
alkine
halo
melanocurtain
acilo
Prior art date
Application number
PE2000000267A
Other languages
English (en)
Inventor
Feng Wang
Frank Hallock Ebetino
Russell James Sheldon
Adam Wieslaw Mazur
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20001641A1 publication Critical patent/PE20001641A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

SE REFIERE A UN PEPTIDO CICLICO DE FORMULA I, DONDE: m, n, q SON 0-4; p ES 0-5; X ES H, HALO, N(R8)SO2R8", SO2R8", SO2-NR8R8`, (CH2)r-PO2HR14, DIFERENTES A E, -(CH2)-m; r ES 0-10; R14 ES OH, H, ALQUILO, ENTRE OTROS; R8 Y R8' SON H, ALQUILO, ACILO, ENTRE OTROS; R8" ES H, ALQUILO, HETEROALQUILO, ENTRE OTROS; O DOS MITADES DE X PUEDE FORMAR ENTRE SI UN ANILLO CONDENSADO CON FENILO; E ES H, HALO, NR13R13', NR13SO2R13", (CH2)rPO2HR15; R15 ES OH, H, ALQUILO, ENTRE OTROS; CUANDO X ES H, E NO ES H, R13 Y R13' SON H, ALQUILO, ACILO, ENTRE OTROS, R13" ES H, ALQUILO, HETEROALQUILO, ENTRE OTROS; Z ES H, OH, HALO, TIOL, OR9, NR9R9', ENTRE OTROS; R9 Y R9' SON H, ALQUILO, ACILO, ENTRE OTROS; DE SNR2C(=NR3)NR4R5, IMIDAZOL, NR4R5; R2 Y R3 SON H, ALQUILO, ALQUENO, ALQUINO O R2 Y R3 O R2 Y R4 O R3 Y R4 O R4 Y R5 JUNTOS SE UNEN PARA FORMAR UN HETEROCICLOALQUILO, HETEROARILO; O R4 Y R5 SON H, ALQUILO, ALQUENO, ALQUINO; R1 Y R1' SON H ALQUILO, ARILO, HETEROARILO, ENTRE OTROS; G ES UN ARILO BICICLICO, HETEROARILOBICICLICO; R11 ES H, ALQUILO, ALQUENO, ARILO, ENTRE OTROS; W ES CH2, CO; M' ES N, CH; B SE ENLAZA A M' Y W Y FORMA UN ANILLO. LOS ANALOGOS DE PEPTIDOS CICLICOS SON DE LOS RECEPTORES DE MELANOCORTINA DE PREFERENCIA PO LOS RECEPTORES MC-4, MC-3
PE2000000267A 1999-03-29 2000-03-29 Ligandos de receptores de melanocortina PE20001641A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12667399P 1999-03-29 1999-03-29

Publications (1)

Publication Number Publication Date
PE20001641A1 true PE20001641A1 (es) 2001-02-07

Family

ID=22426131

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000267A PE20001641A1 (es) 1999-03-29 2000-03-29 Ligandos de receptores de melanocortina

Country Status (34)

Country Link
US (2) US6613874B1 (es)
EP (1) EP1165613B1 (es)
JP (1) JP2002542159A (es)
KR (2) KR100558131B1 (es)
CN (1) CN1249086C (es)
AR (1) AR023201A1 (es)
AT (1) ATE393783T1 (es)
AU (1) AU763510B2 (es)
BR (1) BR0009497A (es)
CA (1) CA2368431C (es)
CO (1) CO5170531A1 (es)
CZ (1) CZ20013407A3 (es)
DE (1) DE60038734T2 (es)
DK (1) DK1165613T3 (es)
ES (1) ES2304345T3 (es)
HK (1) HK1044954B (es)
HU (1) HUP0202203A3 (es)
ID (1) ID30262A (es)
IL (1) IL145406A0 (es)
MA (1) MA25403A1 (es)
MX (1) MXPA01009881A (es)
MY (1) MY126585A (es)
NO (1) NO20014568L (es)
NZ (1) NZ514141A (es)
PE (1) PE20001641A1 (es)
PL (1) PL350095A1 (es)
PT (1) PT1165613E (es)
RU (1) RU2213098C2 (es)
SA (1) SA00210192B1 (es)
SK (1) SK13082001A3 (es)
TR (1) TR200102765T2 (es)
TW (1) TWI250990B (es)
WO (1) WO2000058361A1 (es)
ZA (1) ZA200107411B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
AU766191B2 (en) 1999-06-04 2003-10-09 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
CA2396307A1 (en) * 2000-01-18 2001-07-26 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
CZ2003584A3 (cs) 2000-08-30 2003-08-13 F. Hoffmann-La Roche Ag Selektivní cyklické peptidy
IL154437A0 (en) * 2000-09-27 2003-09-17 Procter & Gamble Melanocortin receptor ligands
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
CA2453515A1 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
KR20060014444A (ko) * 2003-06-19 2006-02-15 일라이 릴리 앤드 캄파니 멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도
RU2381233C2 (ru) * 2003-09-30 2010-02-10 Ново Нордиск А/С Агонисты рецептора меланокортина
AU2015201062B2 (en) * 2003-11-05 2017-03-09 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
PT1680443E (pt) * 2003-11-05 2013-12-11 Harvard College Péptidos alfa-helicoidais estabilizados e suas utilizações
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
US20070123453A1 (en) * 2004-03-29 2007-05-31 Heiman Mark L Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
WO2006041769A2 (en) * 2004-10-05 2006-04-20 Merck & Co., Inc. Methods for the treatment of substance abuse and addiction
WO2006060873A1 (en) * 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
WO2006073771A2 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073772A1 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US7754691B1 (en) 2005-07-07 2010-07-13 Palatin Technologies, Inc. Linear melanocortin receptor-specific peptides for cachexia
WO2007008684A2 (en) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Ligands of melanocortin receptors
DK3354273T3 (da) 2005-07-08 2021-06-28 Ipsen Pharma Melanocortinreceptorligander
EP1968995A1 (en) * 2005-12-30 2008-09-17 F. Hoffmann-la Roche AG Methods for the synthesis of arginine-containing peptides
PL2348016T3 (pl) 2006-06-09 2016-09-30 Pochodne fenylopiroloaminoguanidyny
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
BRPI0720306A2 (pt) 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
ES2648687T3 (es) 2007-02-23 2018-01-05 Aileron Therapeutics, Inc. Péptidos macrocíclicos unidos a triazol
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
ES2618315T3 (es) 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
WO2009099677A2 (en) * 2008-02-08 2009-08-13 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
EP2310407A4 (en) * 2008-04-08 2011-09-14 Aileron Therapeutics Inc BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
TW201002340A (en) * 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
EA018630B1 (ru) 2008-06-09 2013-09-30 Палатин Текнолоджиз, Инк. Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
JP2012503025A (ja) 2008-09-22 2012-02-02 エルロン・セラピューティクス・インコーポレイテッド 精製されたポリペプチド組成物を調製するための方法
BRPI1006139A2 (pt) 2009-01-14 2017-05-30 Aileron Therapeutics Inc macrociclos peptidomiméticos
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
AU2010259008C1 (en) 2009-06-08 2016-04-21 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
BR112012000867A2 (pt) 2009-07-13 2019-09-24 Harvard College "polipeptídeos bifuncional costurado e uso do mesmo"
EP2480565A4 (en) 2009-09-22 2014-01-01 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
JP2013510881A (ja) * 2009-11-16 2013-03-28 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Ａｃ−Ａｒｇ−シクロ（Ｃｙｓ−Ｄ−Ａｌａ−Ｈｉｓ−Ｄ−Ｐｈｅ−Ａｒｇ−Ｔｒｐ−Ｃｙｓ）−ＮＨ２の合成のための方法
AU2010321738B2 (en) 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
CN101824415A (zh) * 2010-03-31 2010-09-08 华东师范大学 黑素皮质1型受体基因的snp及其应用
WO2012021875A1 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with triazole linkers
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AR089993A1 (es) 2012-02-15 2014-10-01 Aileron Therapeutics Inc Macrociclos peptidomimeticos
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
DK2920197T3 (da) 2012-09-26 2021-05-31 Harvard College Prolinlåste sammenhæftede peptider og anvendelser deraf
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
KR20150131244A (ko) 2013-03-13 2015-11-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스테이플드 및 스티치드 폴리펩티드 및 그의 용도
US10227390B2 (en) 2013-06-14 2019-03-12 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
IL288147B2 (en) 2014-05-21 2024-03-01 Harvard College Ras inhibitory peptides and uses thereof
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその製剤
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
SI3773558T1 (sl) 2019-05-10 2022-11-30 Synact Pharma Aps Kombinirano zdravljenje artritične bolezni
CN110681362B (zh) * 2019-09-26 2020-09-11 浙江大学 以羧基和吲哚基为功能基团的混合模式层析介质
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
US11932628B2 (en) 2021-01-04 2024-03-19 Regents Of The University Of Minnesota Selective small molecule peptidomimetic melanocortin ligands
AU2022300305A1 (en) 2021-06-21 2024-01-25 Synact Pharma Aps Salts of phenyl pyrrole aminoguanidine and polymorphs of phenyl pyrrole aminoguanidinium salts

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462927A (en) 1985-04-30 1995-10-31 The Administrators Of The Tulane Educational Fund Peptides aiding nerve regeneration
ATE109793T1 (de) 1987-05-22 1994-08-15 University Patents Inc Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
JP2795449B2 (ja) 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
ZA908610B (en) 1989-11-03 1991-08-28 Univ Tulane Peptides aiding nerve regeneration
DE69212011T2 (de) 1991-02-15 1997-01-09 Takeda Chemical Industries Ltd Endothelin Antagoniste
EP0528312B1 (en) 1991-08-13 1997-07-16 Takeda Chemical Industries, Ltd. Cyclic peptides and use thereof
RU2096415C1 (ru) * 1991-09-30 1997-11-20 Дзе Дюпон Мерк Фармасьютикал Компани Циклические пептиды или их фармацевтически приемлемые соли, фармацевтическая композиция
EP0552417B1 (en) 1991-11-19 1999-07-07 Takeda Chemical Industries, Ltd. Cyclic peptides and use thereof
EP0547317A1 (en) 1991-12-19 1993-06-23 Takeda Chemical Industries, Ltd. Endothelin antagonists
DE9203901U1 (de) 1992-03-24 1992-07-16 Croon & Lucke Maschinenfabrik Gmbh, 7947 Mengen Gestell zum Lagern von flächigen Werkstücken
AU672426B2 (en) 1992-07-27 1996-10-03 Biomeasure, Inc. Neuromedin B receptor antagonists
US5569741A (en) 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
AU673731B2 (en) 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
EP0714909A1 (en) 1994-12-01 1996-06-05 Takeda Chemical Industries, Ltd. Composition for prophylaxis or treatment of pulmonary circulatory diseases
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
EP0822939A1 (en) 1995-04-28 1998-02-11 Takeda Chemical Industries, Ltd. Cyclic pentapeptide lh-rh receptor antagonists
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US6362164B1 (en) 1996-06-11 2002-03-26 Novartis Ag Combination of a somatostatin analogue and a rapamycin
US6858585B1 (en) 1996-06-25 2005-02-22 Nisshin Seifun Group Inc. Cyclic depsipeptides and drugs containing the same as the active ingredient
EP0815870A3 (en) 1996-06-27 2000-05-03 Takeda Chemical Industries, Ltd. Composition for prohylaxis or treatment of cerebral infarction
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
CA2275442A1 (en) 1996-12-17 1998-06-25 Quadrant Holdings Cambridge Limited Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
SE9700620D0 (sv) * 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight

Also Published As

Publication number Publication date
SK13082001A3 (sk) 2002-03-05
RU2213098C2 (ru) 2003-09-27
CN1345335A (zh) 2002-04-17
HK1044954B (en) 2008-11-21
ID30262A (id) 2001-11-15
TWI250990B (en) 2006-03-11
US6951916B2 (en) 2005-10-04
WO2000058361A1 (en) 2000-10-05
AU763510B2 (en) 2003-07-24
IL145406A0 (en) 2002-06-30
JP2002542159A (ja) 2002-12-10
DE60038734T2 (de) 2009-07-02
TR200102765T2 (tr) 2002-05-21
CN1249086C (zh) 2006-04-05
EP1165613A1 (en) 2002-01-02
HUP0202203A2 (en) 2002-10-28
ES2304345T3 (es) 2008-10-16
NO20014568L (no) 2001-11-29
DE60038734D1 (de) 2008-06-12
KR20020008143A (ko) 2002-01-29
CA2368431A1 (en) 2000-10-05
AR023201A1 (es) 2002-09-04
ZA200107411B (en) 2002-05-29
HUP0202203A3 (en) 2003-09-29
MA25403A1 (fr) 2002-04-01
SA00210192B1 (ar) 2006-06-04
ATE393783T1 (de) 2008-05-15
PL350095A1 (en) 2002-11-04
MY126585A (en) 2006-10-31
NZ514141A (en) 2004-01-30
KR100519201B1 (ko) 2005-10-06
MXPA01009881A (es) 2002-05-06
US20040023859A1 (en) 2004-02-05
CO5170531A1 (es) 2002-06-27
EP1165613B1 (en) 2008-04-30
CZ20013407A3 (cs) 2002-02-13
DK1165613T3 (da) 2008-08-25
BR0009497A (pt) 2002-01-15
US6613874B1 (en) 2003-09-02
AU4017900A (en) 2000-10-16
CA2368431C (en) 2006-01-24
KR20050009722A (ko) 2005-01-25
HK1044954A1 (en) 2002-11-08
KR100558131B1 (ko) 2006-03-10
NO20014568D0 (no) 2001-09-20
PT1165613E (pt) 2008-07-29

Similar Documents

Publication Publication Date Title
PE20001641A1 (es) Ligandos de receptores de melanocortina
PE20021087A1 (es) Ligandos receptores de melanocortina
TR200102957T2 (tr) Sitalopram hazırlanması için metod.
EP1323710A4 (en) NITROGEN-BASED NITROGENIC COMPOUNDS
NO20026253D0 (no) Organiske forbindelser
SE9301911D0 (sv) New peptide derivatives
ATE366249T1 (de) Zyklische amid-derivate
TR200003598T2 (tr) Amid türevleri ve nosiseptin antagonistleri
EA200300428A1 (ru) Антагонисты метаботропных рецепторов глутамата
ATE268806T1 (de) Lichtemittierende dendrimere
EA199800051A1 (ru) Производные бензамида и их применение в качестве антагонистов вазопрессина
PE20021094A1 (es) Derivados de ciclohexano-1,4-diamina sustituidos
EP0933354A4 (en) CONNECTIONS INFLUENCING THE ACTIVITY OF CALCIUM RECEPTORS
NZ511739A (en) New esters derived from substituted phenyl-cyclohexyl compounds
EP1468990A4 (en) PIPERAZINE DERIVATIVE
PE20020406A1 (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS 2,6-DISUSTITUIDAS COMO INHIBIDORES DE LAS PROTEINAS CINASAS
DE50311208D1 (de) Verfahren zur Herstellung von Polyhalogenalkylaryl-Verbindungen
ES2180201T3 (es) Derivados de azetidinona para el tratamiento de infecciones por hcmv.
DE60136476D1 (de) -stickstoffhaltigen zyklischen polyaminen und deren verbindungen
PE20021046A1 (es) Sulfonilguanidina que tiene afinidad al punto de fijacion de gabapentina
UA41300C2 (uk) Аналоги гормонів-антагоністів lhrh і спосіб їх отримання
ATE198599T1 (de) Guanidinium-verbindungen, pharmazeutische präparate davon und ihre verwendungen
TR200400293T4 (tr) 9-dihidro-13-asetilbasatin III'e ait suda çözünebilir 9-dihidro-paklitaksel türevlerinin sentezi.
EA200400739A1 (ru) Способ получения производных [1,4,5]оксадиазепина
EP1310490A4 (en) GPR14 ANTAGONIST

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed